Two new studies use new models to identify genetic targets and test promising treatments in adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year after starting treatment remains on the drug with 77 percent tumor reduction and no new metastases.
from Top Health News -- ScienceDaily http://ift.tt/2FPQZYk
No comments:
Post a Comment